Working… Menu

Betaseron Pregnancy Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00317564
Recruitment Status : Completed
First Posted : April 25, 2006
Last Update Posted : December 12, 2018
Information provided by (Responsible Party):
Syneos Health

Brief Summary:
This is a prospective, observational, registration and follow-up study of women exposed to Betaseron® at the time of conception (i.e., any time from the first day of the last menstrual period) and/or during pregnancy. The Betaseron® Pregnancy Registry is designed to determine whether there is an increased risk or a pattern of birth defects in the offspring of women exposed to Betaseron® at conception and during pregnancy compared to rates from women in the general US population. Secondarily, the Registry will examine rates of spontaneous abortions and other negative pregnancy outcomes in this population. This study will be conducted in the United States (US). The Betaseron® Pregnancy Registry is sponsored by Bayer HealthCare Pharmaceuticals and is managed by the Post Approval & Strategic Services group at INC Research, LLC. The scientific conduct and analysis of the Registry will be overseen by an Independent Data Safety Monitoring Board (IDSMB) consisting of external specialists in teratology, epidemiology, maternal and fetal medicine, and neurology (external member details available upon request).

Condition or disease
Birth Defects Pregnancy Complications Multiple Sclerosis

Detailed Description:

Because informed consent is required, the Registration process must be initiated by the patient. An HCP who contacts the Registry may request an authorization for release of medical information packet or have the eligible patient contact the Registry directly. Once an eligible subject provides consent and permission to obtain information from her HCP, the Registry will contact the obstetric HCP and obtain information on demographics, history of previous pregnancies, maternal risk factors, pregnancy outcome, and neonatal health. Data will be collected from the maternal HCP at enrollment, during the second trimester (around week 20), and at outcome. Data on live born infants will be collected from the pediatrician at 4 months of age. If a birth defect is reported, targeted follow-up may be conducted.

NOTE: This study has previously been posted by Berlex, Inc. which has since been renamed to Bayer HealthCare Pharmaceuticals, Inc. Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of this pregnancy registry.

Layout table for study information
Study Type : Observational
Actual Enrollment : 113 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Betaseron Pregnancy Registry
Study Start Date : April 2006
Actual Primary Completion Date : April 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
US only

Inclusion Criteria:

The subjects must meet the following criteria for registration:

  • Enroll prospectively (patient is still pregnant and no structural defects have been noted on a prenatal test)
  • Diagnosed with MS prior to or during the current pregnancy
  • Exposed to Betaseron® on or after the first day of the patient's last menstrual period
  • Provide verbal consent to participate in the Registry
  • Verbally provide contact information for herself, her HCP, and the infant's HCP (as applicable)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00317564

Layout table for location information
United States, North Carolina
INC Research
Wilmington, North Carolina, United States, 28405
Sponsors and Collaborators
Syneos Health
Layout table for investigator information
Principal Investigator: Jessica Albano, PhD, MS Syneos Health
Study Director: Vicki Poon, MPH Bayer
Study Director: Mark Rametta, D.O., FACOI, FACP Bayer
Study Director: Karen Maloney Marini Bayer
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Syneos Health Identifier: NCT00317564    
Other Study ID Numbers: 308740
First Posted: April 25, 2006    Key Record Dates
Last Update Posted: December 12, 2018
Last Verified: December 2018
Keywords provided by Syneos Health:
Birth Defects
High Risk Pregnancy
Multiple Sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pregnancy Complications
Congenital Abnormalities
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases